medigraphic.com
ISSN 0187-5337 (Print)
Instituto Nacional de Perinatología

2001, Number 2

<< Back Next >>

Perinatol Reprod Hum 2001; 15 (2)

Morbilidad neonatal y alteraciones del neurodesarrollo al año de vida, en neonatos que recibieron surfactante

Fernández-Carrocera LA, Barrera-Reyes RH, Arreola-Ramírez G, Martínez-Cruz C

Language: Spanish
References: 31
Page: 139-144
PDF size: 111.21 Kb.


ABSTRACT

Introduction: It has been informed that the use of exogenous surfactant has reduced the perinatal pathologies that can produce handicap, although some metaanalysis do not support these affirmations. The objective was to compare the neonatal morbidity and neurodevelopment alterations at the first year of age in a group of neonates with respiratory distress syndrome (RDS) that received surfactant with those ones that didn’t.
Material and methods: A group of children born between 1996 and 1998 with RDS at birth, who received exogenous surfactant were evaluated; neonates with RDS that were born between 1991 and 1993 were included as a group control, period in which surfactant was not used by the Institute. To evaluate neurological function Amiel Tisón test was used, the auditory tests were accomplished in a chamber, with MAICO M-22 audiometer of two channels.
Results: 155 patients with surfactant and 157 without surfactant were studied, synthetic surfactant use was a protective factor for necrotizing enterocolitis OR (0.38 CI 95% O.18-0.79), pneumonia (0.33 CI 95% O.21-0.53), intraventricular hemorrhage III/IV degrees (0.46 CI 95% 0.22-0.96) and a risk factor for pulmonary interstitial emphysema (10.7 CI 95% 1.36-85); an increase in the risk of the development alterations was not found for the neurological type, but surfactant we was protective factor for general auditive alterations and for the severe/deep type was still found (0.35, CI 95% 0.15-0.79 and 0.42, CI 95% 0.18-0.96, respectively).
Conclusions: A decrease in the risk for necrotizing enterocolitis, pneumonia, intraventricular hemorrhage III/IV degree and auditive alterations was found, there were no differences in the neurological alterations of neonates treated with surfactant with those that didn’t however the risk increased for intersticial emphysema.


REFERENCES

  1. Avery ME, Mead J. Surface properties in relation to atelectasis and hyaline membrane disease. Am J Dis Child 1959; 96: 517-23.

  2. Liggins GC. Premature delivery of fetal lambs infused with glucocorticoids. J Endocrinol 1969; 5: 515-23.

  3. Fujiwara T, Maeta H, Chida S, Morita T, Watabe Y, Abe T. Artificial surfactant therapy in hyalinemembrane disease. Lancet 1980; 1: 55-9.

  4. Jobe AH. Drug therapy: Pulmonary surfactant therapy. N Engl J Med 1993; 328: 861-8.

  5. Horbar JD, Wright EC, Onstad L. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601 to 1300 grams at birth. Pediatrics 1993; 92: 191-6.

  6. Schwartz RM, Luby AM, Scalon JW, Kellogg RJ. Effect of surfactant on morbidity, mortality and resource use in newborn infants weighing 500 to 1500 g. N Engl J Med 1994; 330: 1476-80.

  7. Kending JW, Ryan RM, Sinkin RA, Robert A, Maniscalco WM, Notter RH, y col. Comparison of two strategies for surfactant prophylaxis in very premature infant. A multicenter randomized trial. Pediatrics 1998; 101: 1006-12.

  8. Soll F. Prophylactic natural surfactant extracts for preventing mortality and morbidity in preterm infants (Cochrane Review) The Cochrane Library. Issues 2, 2000 Oxoford: Update software.

  9. Soll RF, Morley CJ. Prophylactic versus selective use of surfactant for preventing morbidity and mortality in preterm infants. (Cochrane Review) The Cochrane Library. Issues 2, 1999 Oxoford: Update software.

  10. Soll RF. Synthetic surfactant for respiratory distress syndrome in preterm infants. (Cochrane Review) The Cochrane Library. Issues 2, 1999 Oxoford: Update software.

  11. Diaz Rossello J, Estol PH, Martell M, Del Barco M, Margotto P, Grandzoto J, Bastida J, Peña J, Villanueva D. Hyaline membrane disease (HMD) therapy in Latin America: Impact of exogenous surfactant administration on newborn survival, morbidity and use of resources. J Perinat Med 1977; 25: 280-7.

  12. Smyth J, Allen A, MacMurray B, Peliowski A, Sankaran K, Volberg F, Shukla A, Long W. Double -blind, randomized placebocontrolled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500 to 749 grams with respiratory distress syndrome. J Pediatr 1995; 126: 81-9.

  13. Casiro O, Bingham W, MacMurray B, Whitfield M, Saigal S, Vincer M, Long W. One-year followup of 89 infants with birth weights of 500 to 749 grams and respiratory distress syndrome randomized to two rescue doses of synthetic surfactant or air placebo. J Pediatr 1995; 126: 53-60.

  14. Corbet A, Long W, Schumacher R, Gerdes J, Cotton R. Double-blind developmental evaluation at 1-year corrected age of 597 premature infants with birth weights from 500 to 1350 grams enrolled in three placebo-controlled trials of prophylactic synthetic surfactant. J Pediatr 1995; 126: 5-12.

  15. Walther FJ, Mullett M, Schumacher R, Sundell H, Easa D, Long W. One-year follow-up of 66 premature infants weighing 500 to 699 grams treated with a single dose of synthetic surfactant or air placebo at birth: Results of a double-blind trial. J Pediatr 1995; 126: 13-9.

  16. Krabyl E, Bose CL, Corbet AJ, García- Prats J, Asbill D, Edwards K, Long W. Double-blind evalua-tion of development and health status to age 2 years of infants weighing 700 to 1350 grams treated prophylactically at birth with a single dose of synthetic surfactant or air placebo. J Pediatr 1995; 126: 33-42.

  17. Gerdes J, Gerdes M, Beaumont E, Cook L, Dhaniereddy R, Kopleman A, Jarrett R, Long W. Health and neurodevelopmental at 1-year adjusted age in 508 infants weighing 700 to 1100 grams who received prophylaxis with one versus three doses of synthetic surfactant. J Pediatr 1995; 126: 26-32.

  18. Sauve R, Long W, Voncer M, Brad H, Derleth D, Stevenson D, Pauly T, Robertson C. Outcome at 1-year adjusted age of 957 weighing more than 1250 grams with respiratory distress syndrome rando-mized to receive synthetic surfactant or air placebo. J Pediatr 1995; 126: 78-80.

  19. Courtney S, Long W, McMillan D, Walter D, Thompson T, Sauve R, Conway B, Bard H. Double blind 1-year follow-up of 1540 infants with respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air in four clinical trials. J Pediatr 1995; 126: 543-52.

  20. Gong A, Anday E, Boros S, Bucciarelli R, Burchfield D, Zucker J, Long W. One-year follow-up evaluation of 260 premature infants with respiratory distress syndrome and birth weights of 700 to 1350 grams randomized to two rescue doses of synthetic surfactant or air placebo. J Pediatr 1995; 126: 68-74.

  21. Sell M, Cotton R, Hirata T, Guthrie R, LeBlanc M, Mammel M, Long W. One year follow-up of 273 infants with birth weights of 700 to 1100 grams after prophylactic treatment of respiratory distress syndrome with synthetic surfactant or air placebo. J Pediatr 1995; 126: 20-5.

  22. Saigal S, Robertson C, Sankaran K, Bingham W, Casiro O, MacMurrayB, Whitfield M, Long W. One-year outcome in 232 premature infants with birth of 750 to 1249 grams and respiratory distress syndrome randomized to rescue treatment with two doses of synthetic surfactant or air placebo. J Pediatr 1995; 126: 61-7.

  23. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. (Cochrane Review) The Cochrane Library. Issues 2, 1999. Oxoford: Update software.

  24. Soll RF. Multiple versus single dose natural surfactant extract for severe neonatal respiratory distress syndrome. (Cochrane Review) The Cochrane Library. Issues 2, 1999. Oxoford: Update software.

  25. Amiel Tison C, Grenier A. Valoración neurológica del recién nacido y lactante. Buenos Aires: Ed T. Masón; 1984.

  26. Northem JL, downs MP. Pruebas audiológicas clínicas. La audición en los niños. Ed. Salvat; España: 1981.

  27. Bregman J. Developmental outcome in very low birth weight infants Pediatric Clin North Am 1998; 45: 673-90.

  28. National Institutes of health consensus development conference statement. Am J Obstet Gynecol 1995; 173: 246-52.

  29. Wright LL, Horbar JD, Gunkel H, Verter J, Younes N, Andrews EB, Long W. Evidence from multicenter networks on the current use and effectiveness of antenatal corticoids on low birth weight infants. Am J Obstet Gynecol 1995; 173: 263-9.

  30. Crowther CA, Henderson-Smart DJ. Phenobarbital prior to preterm birth for the prevention of neonatal periventricular haemorrhage (PVH) (Cochrane Review) The Cochrane Library. Issues 2, 1999 Oxoford: Update software.

  31. Fowlie PW. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight infants. 1999 Issue 2 The Cochrane Library.




2020     |     www.medigraphic.com